System to reduce defibrillation requirements
CA 2267162 A1 · Owner: Cardiac Pacemakers, Inc. · Inventors: Kenknight, Bruce H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A hybrid tachyarrhythmia therapy utilizes a combination of two therapies: pacing therapy (optionally followed by therapy employing waveforms having morphologies congruent to defibrillation waveforms but at reduced strength); and defibrillation (including cardioversion) therapy. The two therapies are applied in either a temporally concident or an immediately sequential, fashion. At least one pacing pulse that influences only a localized portion of selected cardiac tissue is applied, prior to or coincident with at least one defibrillation-level shock. The defibrillation shock strength (voltage and/or energy) required to terminate the tachyarrhythmia is less than would be required in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 25, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 25, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 25, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.